New Results
A screen for combination therapies in BRAF/NRAS wild type melanoma identifies nilotinib plus MEK inhibitor as a synergistic combination
Marco Ranzani, Kristel Kemper, Magali Michaut, Oscar Krijgsman, Nanne Aben, Vivek Iyer, Kim Wong, Theodoros I. Roumeliotis, Martin Del Castillo Velasco-Herrera, Jérémie Nsengimana, Gemma Turner, Nicola Thompson, Aida Shahrabi, Marcela Sjoberg, Mamunur Rashid, Anneliese O. Speak, Vera Grinkevich, Fiona Behan, David Tamborero, Francesco Iorio, Stijn van Dongen, Graham R. Bignell, Clara Alsinet, Sofia Chen, Emmanuelle Supper, Ken Dutton-Regester, Antonia Pritchard, Chi Wong, Anton Enright, Julia Newton-Bishop, Ultan McDermott, Nicholas K. Hayward, Jyoti S. Choudhary, Kosuke Yusa, Lodewyk Wessels, Mathew J. Garnett, Daniel Peeper, David J. Adams
doi: https://doi.org/10.1101/195354
Marco Ranzani
1Experimental Cancer Genetics, The Wellcome Trust Sanger Institute, Hinxton, Cambridge, CB10 1SA, United Kingdom
Kristel Kemper
2Division of Molecular Oncology, The Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands
Magali Michaut
3Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands
Oscar Krijgsman
2Division of Molecular Oncology, The Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands
Nanne Aben
3Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands
Vivek Iyer
1Experimental Cancer Genetics, The Wellcome Trust Sanger Institute, Hinxton, Cambridge, CB10 1SA, United Kingdom
Kim Wong
1Experimental Cancer Genetics, The Wellcome Trust Sanger Institute, Hinxton, Cambridge, CB10 1SA, United Kingdom
Theodoros I. Roumeliotis
4Mass Spectrometry, The Wellcome Trust Sanger Institute, Hinxton, Cambridge, CB10 1SA, United Kingdom, and Functional Proteomics Group, Chester Beatty Laboratories, The Institute of CancerResearch, London SW3 6JB, United Kingdom
Martin Del Castillo Velasco-Herrera
1Experimental Cancer Genetics, The Wellcome Trust Sanger Institute, Hinxton, Cambridge, CB10 1SA, United Kingdom
Jérémie Nsengimana
5Leeds Institute of Cancer and Pathology, University of Leeds, Cancer Genetics Building,St James's University Hospital, Beckett Street, Leeds, LS9 7TF, United Kingdom
Gemma Turner
1Experimental Cancer Genetics, The Wellcome Trust Sanger Institute, Hinxton, Cambridge, CB10 1SA, United Kingdom
Nicola Thompson
1Experimental Cancer Genetics, The Wellcome Trust Sanger Institute, Hinxton, Cambridge, CB10 1SA, United Kingdom
Aida Shahrabi
2Division of Molecular Oncology, The Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands
Marcela Sjoberg
1Experimental Cancer Genetics, The Wellcome Trust Sanger Institute, Hinxton, Cambridge, CB10 1SA, United Kingdom
Mamunur Rashid
1Experimental Cancer Genetics, The Wellcome Trust Sanger Institute, Hinxton, Cambridge, CB10 1SA, United Kingdom
Anneliese O. Speak
1Experimental Cancer Genetics, The Wellcome Trust Sanger Institute, Hinxton, Cambridge, CB10 1SA, United Kingdom
Vera Grinkevich
6Cancer Genome Project, The Wellcome Trust Sanger Institute, Hinxton, Cambridge, CB10 1SA, United Kingdom
Fiona Behan
6Cancer Genome Project, The Wellcome Trust Sanger Institute, Hinxton, Cambridge, CB10 1SA, United Kingdom
David Tamborero
7Research Program on Biomedical Informatics, IMIM Hospital del Mar Medical Research Instituteand Universitat Pompeu Fabra, Doctor Aiguader 88, 08003, Barcelona, Catalonia, Spain
Francesco Iorio
8European Molecular Biology Laboratory - European Bioinformatics Institute, Wellcome Genome Campus, Cambridge, CB10 1SD, United Kingdom
Stijn van Dongen
8European Molecular Biology Laboratory - European Bioinformatics Institute, Wellcome Genome Campus, Cambridge, CB10 1SD, United Kingdom
Graham R. Bignell
6Cancer Genome Project, The Wellcome Trust Sanger Institute, Hinxton, Cambridge, CB10 1SA, United Kingdom
Clara Alsinet
1Experimental Cancer Genetics, The Wellcome Trust Sanger Institute, Hinxton, Cambridge, CB10 1SA, United Kingdom
Sofia Chen
1Experimental Cancer Genetics, The Wellcome Trust Sanger Institute, Hinxton, Cambridge, CB10 1SA, United Kingdom
Emmanuelle Supper
1Experimental Cancer Genetics, The Wellcome Trust Sanger Institute, Hinxton, Cambridge, CB10 1SA, United Kingdom
Ken Dutton-Regester
9Oncogenomics Laboratory, QIMR Berghofer, Medical Research Institute, Brisbane, Queensland, Australia
Antonia Pritchard
9Oncogenomics Laboratory, QIMR Berghofer, Medical Research Institute, Brisbane, Queensland, Australia
Chi Wong
1Experimental Cancer Genetics, The Wellcome Trust Sanger Institute, Hinxton, Cambridge, CB10 1SA, United Kingdom
Anton Enright
8European Molecular Biology Laboratory - European Bioinformatics Institute, Wellcome Genome Campus, Cambridge, CB10 1SD, United Kingdom
Julia Newton-Bishop
5Leeds Institute of Cancer and Pathology, University of Leeds, Cancer Genetics Building,St James's University Hospital, Beckett Street, Leeds, LS9 7TF, United Kingdom
Ultan McDermott
6Cancer Genome Project, The Wellcome Trust Sanger Institute, Hinxton, Cambridge, CB10 1SA, United Kingdom
Nicholas K. Hayward
9Oncogenomics Laboratory, QIMR Berghofer, Medical Research Institute, Brisbane, Queensland, Australia
Jyoti S. Choudhary
4Mass Spectrometry, The Wellcome Trust Sanger Institute, Hinxton, Cambridge, CB10 1SA, United Kingdom, and Functional Proteomics Group, Chester Beatty Laboratories, The Institute of CancerResearch, London SW3 6JB, United Kingdom
Kosuke Yusa
10Cellular Genomics, The Wellcome Trust Sanger Institute, Hinxton, Cambridge CB10 1SA, United Kingdom
Lodewyk Wessels
3Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands
Mathew J. Garnett
6Cancer Genome Project, The Wellcome Trust Sanger Institute, Hinxton, Cambridge, CB10 1SA, United Kingdom
Daniel Peeper
2Division of Molecular Oncology, The Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands
David J. Adams
4Mass Spectrometry, The Wellcome Trust Sanger Institute, Hinxton, Cambridge, CB10 1SA, United Kingdom, and Functional Proteomics Group, Chester Beatty Laboratories, The Institute of CancerResearch, London SW3 6JB, United Kingdom
- Supplementary Figures 1-5
- Supplementary Table 1
- Supplementary Table 2
- Supplementary Table 3
- Supplementary Table 4
- Supplementary Table 5
- Supplementary Table 6
- Supplementary Table 7
- Supplementary Table 8
- Supplementary Table 9
- Supplementary Table 10
- Supplementary Table 11
- Supplementary Table 12
- Supplementary Table 13
- Supplementary Table 14
- Supplementary Table 15
- Supplementary Table 16
- Supplementary Table 17
- Supplementary Table 18
- Supplementary Table 19
- Supplementary Table 20
- Supplementary Table 21
Posted September 28, 2017.
A screen for combination therapies in BRAF/NRAS wild type melanoma identifies nilotinib plus MEK inhibitor as a synergistic combination
Marco Ranzani, Kristel Kemper, Magali Michaut, Oscar Krijgsman, Nanne Aben, Vivek Iyer, Kim Wong, Theodoros I. Roumeliotis, Martin Del Castillo Velasco-Herrera, Jérémie Nsengimana, Gemma Turner, Nicola Thompson, Aida Shahrabi, Marcela Sjoberg, Mamunur Rashid, Anneliese O. Speak, Vera Grinkevich, Fiona Behan, David Tamborero, Francesco Iorio, Stijn van Dongen, Graham R. Bignell, Clara Alsinet, Sofia Chen, Emmanuelle Supper, Ken Dutton-Regester, Antonia Pritchard, Chi Wong, Anton Enright, Julia Newton-Bishop, Ultan McDermott, Nicholas K. Hayward, Jyoti S. Choudhary, Kosuke Yusa, Lodewyk Wessels, Mathew J. Garnett, Daniel Peeper, David J. Adams
bioRxiv 195354; doi: https://doi.org/10.1101/195354
A screen for combination therapies in BRAF/NRAS wild type melanoma identifies nilotinib plus MEK inhibitor as a synergistic combination
Marco Ranzani, Kristel Kemper, Magali Michaut, Oscar Krijgsman, Nanne Aben, Vivek Iyer, Kim Wong, Theodoros I. Roumeliotis, Martin Del Castillo Velasco-Herrera, Jérémie Nsengimana, Gemma Turner, Nicola Thompson, Aida Shahrabi, Marcela Sjoberg, Mamunur Rashid, Anneliese O. Speak, Vera Grinkevich, Fiona Behan, David Tamborero, Francesco Iorio, Stijn van Dongen, Graham R. Bignell, Clara Alsinet, Sofia Chen, Emmanuelle Supper, Ken Dutton-Regester, Antonia Pritchard, Chi Wong, Anton Enright, Julia Newton-Bishop, Ultan McDermott, Nicholas K. Hayward, Jyoti S. Choudhary, Kosuke Yusa, Lodewyk Wessels, Mathew J. Garnett, Daniel Peeper, David J. Adams
bioRxiv 195354; doi: https://doi.org/10.1101/195354
Subject Area
Subject Areas
- Biochemistry (11718)
- Bioengineering (8724)
- Bioinformatics (29132)
- Biophysics (14936)
- Cancer Biology (12051)
- Cell Biology (17360)
- Clinical Trials (138)
- Developmental Biology (9406)
- Ecology (14146)
- Epidemiology (2067)
- Evolutionary Biology (18269)
- Genetics (12223)
- Genomics (16768)
- Immunology (11844)
- Microbiology (28016)
- Molecular Biology (11560)
- Neuroscience (60822)
- Paleontology (450)
- Pathology (1864)
- Pharmacology and Toxicology (3231)
- Physiology (4940)
- Plant Biology (10401)
- Synthetic Biology (2878)
- Systems Biology (7333)
- Zoology (1642)